A federal comment window shaping how negotiated Medicare drug prices will reach pharmacies and medical providers in 2028 closes on September 18. The Centers for Medicare & Medicaid Services is not reopening which medicines will be negotiated; it is asking for feedback on the machinery that will make the maximum fair price available after a covered drug is dispensed or administered. The deadline matters because the draft reaches beyond manufacturers to Part D plans, Medicare Advantage organizations, pharmacies and Part B providers.
CMS Is Testing the Payment Machinery, Not the Negotiated Price
The CMS fact sheet published July 16 gives interested parties 60 days to respond. Comments received by 11:59 p.m. Pacific on September 18, 2026 will be considered as the agency prepares final guidance for release in the fall. That makes the date a comment deadline, not an enrollment cutoff or a date when a beneficiary must file for a lower prescription price.
The draft centers on “effectuation,” the process for making an agreed maximum fair price available in actual transactions. A primary manufacturer may arrange for an acquisition price no higher than the negotiated amount before the sale, or provide a retrospective payment for the difference afterward. CMS is seeking workable rules for Part B drugs administered in offices and hospitals while also updating the system already being used for selected Part D drugs.
Part B creates a harder data problem than a retail prescription. Medicare Administrative Contractors process Original Medicare claims, Medicare Advantage organizations submit encounter data, and a single administered drug may be identified through both billing codes and National Drug Codes. The draft asks how those records should move through the Medicare Transaction Facilitator so a manufacturer can verify an eligible claim without forcing a physician practice to reconstruct the transaction independently.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. The free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
The Draft Builds a 14-Day Refund Clock for Part B Claims
CMS proposes a 14-day payment window after the facilitator sends claim-level information to the manufacturer. The same timetable already anchors the Part D process, and the agency wants operational consistency when negotiated prices expand to selected Part B drugs in 2028. The clock would govern payments between manufacturers and dispensing entities or providers; it is not a promise that a Medicare patient receives a check 14 days after treatment.
The amount of a retrospective payment is another unsettled piece. Providers may have difficulty documenting a reliable acquisition cost for every unit, so the guidance presents several standardized approaches based on wholesale acquisition cost or average sales price. Each option moves complexity differently among manufacturers, providers and Medicare data systems. A formula that is easy to administer may approximate a provider’s cost less precisely, while a more exact formula may require information that claims do not currently carry.
The draft also addresses duplicate discounts under the federal 340B program. A manufacturer does not have to provide the same price concession twice when a selected drug is already subject to a lower 340B ceiling price. CMS says it is not assuming responsibility for resolving every overlap, leaving manufacturers and covered entities with a reconciliation problem that can affect whether payments are timely and correctly calculated.
Another question is what happens when transaction data are incomplete or disputed. The facilitator is meant to connect claim information with manufacturer payment records, but it does not eliminate differences among pharmacy claims, physician-administered drugs and Medicare Advantage encounter files. Commenters can use the open record to show where a required identifier does not exist, where a timetable conflicts with ordinary claims processing, or where a proposed responsibility falls on an organization that cannot perform it.
What Final Guidance Will Decide Before 2028
For Medicare Advantage, CMS is considering whether contracts should require Part B providers that furnish selected drugs to enroll in the facilitator’s data module. It is also asking whether encounter data should arrive faster and include more precise product identifiers. Those choices determine how quickly a claim can be matched to the drug, patient eligibility and the manufacturer responsible for providing access to the negotiated price.
The agency’s negotiation guidance library separates this effectuation draft from the documents governing drug selection, negotiation and prior price years. That distinction keeps the September proceeding in its proper lane: the underlying Medicare negotiation program is already established by statute, while the operational rules for delivering 2028 prices are still being refined.
The patient-facing consequence appears downstream. When a selected Part B drug uses coinsurance, CMS intends the Medicare Advantage member’s in-network charge to be based on a price no higher than the maximum fair price. Whether the supporting payment arrives prospectively or as a refund to the provider changes the administrative route, but the draft’s stated objective is to keep the negotiated amount connected to the cost-sharing calculation rather than stranded in a manufacturer-provider reconciliation.
CMS says final guidance issued later in 2026 will supersede only the 2028 effectuation sections addressed by the draft. Existing policies for 2026 and 2027 remain in force. The September 18 cutoff therefore closes a narrow but consequential record: the last formal chance in this cycle for affected organizations to argue that a data field, enrollment mandate, refund formula or payment deadline will fail before it becomes part of the 2028 operating system.
The Medicare Rules Outside This Comment Record
The CMS proceeding concerns how negotiated prices move through the drug-payment system, not the separate assistance programs that older households must apply for. Medicare Savings Programs and Extra Help use their own income limits and filing paths, which are not resolved by this guidance.
The 69-page guide covers 11 programs, their 2026 income limits and a 50-state phone directory, with a printable tracker included with the download.
Read the program list and filing references in The Benefits Checklist.
This article was researched and drafted with AI assistance and reviewed against primary sources before publication.
